Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension

American Journal of Hypertension

Volumn 10, Issue 7 I, 1997, Pages 735-742

  Oparil, S ^a   Kobrin, I ^a   Abernethy, D R ^a   Levine, B S ^a   Reif, M C ^a   Shepherd, A M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Dose range; Hypertension; Mibefradil

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL; PLACEBO;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPOTENSION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0030872647     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00092-7     Document Type: Article

References (19)

1. 2+ channel blocker with potent vasodilatory but weak inotropic action J Cardiovasc Pharmacol 13 1989 754 759
2. 2+ channel in cardiac tissue Eur J Pharmacol 290 1995 155 158
3. ++ channels J Pharm Exp Ther 271 1994 1483 1488
4. 2+ channels by Ro 40-5967 Circ Res 75 1994 144 148
5. JP Clozel W Osterrieder CH Kleinbloesem Ro 40-5967 a new nondihydropyridine calcium antagonist Cardiovasc Drug Rev 9 1991 4 17
6. HA Welker H Eggers CH Kleinbloesem Ro 40-5967 pharmacokinetics of a new calcium antagonist (abst) Eur J Clin Pharmacol 36(suppl) 1989 A304
7. JP Clozel L Banken W Osterrieder Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs comparison with verapamil J Cardiovasc Pharmacol 14 1989 713 721
8. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts Cardiovasc Drug Ther 4 1990 731 736
9. MCM Portegies R Schmitt CJ Kraaij Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris J Cardiovasc Pharmacol 18 1991 746 751
10. Rousseau MF, Hayashida W, van Eyll C, et al: Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol (in press).
11. PJLM Bernink G Prager A Schelling I Kobrin The Mibefradil International Study Group Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonist? Hypertension 27 1996 426 432
12. ALM Bakx EE van der Wall S Braun Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris a multicenter, placebo-controlled study Am Heart J 130 1995 748 757
13. R Schmitt CH Kleinbloesem GG Belz Hemodynamic and humoral effect of the novel calcium antagonist Ro 40-5967 in patients with hypertension Clin Pharmacol Ther 52 1992 314 323
14. PA Meredith D Perloff G Mancia T Pickering Blood pressure variability and its implications for antihypertensive therapy Blood Pressure 5 1995 5 11
15. RF Gillum DM Makuc JJ Feldman Pulse rate, coronary heart disease and death the NHANES I Epidemiologic Follow-up Study Am Heart J 121 1991 172 177
16. E Thaulow JE Erikssen How important is heart rate? J Hypertens 9(suppl 17) 1991 527 530
17. AR Dyer V Persky J Stamler Heart rate as a prognostic factor for coronary heart disease and mortality findings in three Chicago epidemiologic studies Am J Epidemiol 112 1980 736 749
18. A Perski G Olsson C Landou U Faire T Theorell A Hamsten Minimum heart rate and coronary atherosclerosis independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age Am Heart J 123 1992 609 619
19. JL Reid PA Meredith Concentration-effect analysis of antihypertensive drug responses Hypertension 16 1990 12 18